A comparison of the clinical efficacies of Intense Pulsed Light (IPL), PhotoDynamic Therapy (PDT) and adapalene in the treatment of mild to moderate acne vulgaris
| ISRCTN | ISRCTN52474223 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN52474223 |
| EudraCT/CTIS number | 2008-000475-25 |
| Secondary identifying numbers | 07/CMC/4136E |
- Submission date
- 07/04/2008
- Registration date
- 30/05/2008
- Last edited
- 19/05/2022
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Skin and Connective Tissue Diseases
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Plain English summary of protocol
Not provided at time of registration
Contact information
Prof M Gonzalez
Scientific
Scientific
Reader in Dermatology
Department of Dermatology
3rd Floor Glamorgan House
School of Medicine
Heath Park
Cardiff University
Cardiff
CF14 4XN
United Kingdom
Study information
| Study design | Double-blind parallel assignment randomised active controlled efficacy/safety study |
|---|---|
| Primary study design | Interventional |
| Secondary study design | Randomised controlled trial |
| Study setting(s) | Other |
| Study type | Treatment |
| Participant information sheet | Not available in web format, please contact project coordinator, Dr Chantal Suthananthan (details below), to request a patient information sheet |
| Scientific title | Randomised, controlled, double-blind, parallel group clinical trial evaluating the efficacies and safety of methyl-aminolevulinate photodynamic therapy (PDT-MAL) and intense pulsed light, administered as placebo-photodynamic therapy (PDT-placebo), compared with the efficacy of adapalene 0.1% gel in the treatment of adults with mild to moderate acne vulgaris |
| Study objectives | Placebo photodynamic therapy (PDT) is at least as efficacious as adapalene 0.1% gel, and methyl-aminolevulinate (MAL)-PDT is more efficacious than either modality. MAL-PDT may also have a longer treatment-free period of acne remission. On 11/02/2009 this record was updated to include amended trial dates. The initial trial dates at the time of registration were: Initial anticipated start date: 01/06/2008 Initial anticipated end date: 01/06/2012 On 04/11/2009 this record was extensively updated. All updates can be found under the relevant field with the above update date. Please also note that the application regimen of MAL/placebo has been changed from 30 minutes without occlusion to 60 minutes with occlusion. |
| Ethics approval(s) | Submitted to the South Wales Research Ethics Committee approval pending as of 11/02/2009 |
| Health condition(s) or problem(s) studied | Acne |
| Intervention | Treatment schedule: PDT-MAL arm: Full-face treatments every 2 weeks x 4 PDT-Placebo arm: Full-face treatments every 2 weeks x 4 Adapalene group: Participants instructed to use adapalene as monotherapy nightly MAL cream (Metvix®): For this research, we would like to achieve a good balance between efficacy, short treatment times and very minimal side-effects. Hence, short-contact (60 minutes) MAL cream will be used as the photosensitiser in this study. Metvix® will be applied as a 1-mm film to the face, with occlusion, avoiding the areas immediately around the eyes, nose and lips. Patients will sit for 60 minutes in a darkened room. Prior to illumination, subjects will be asked to wash their faces using a gentle cleanser. Placebo cream (Unguentum M®): Unguentum M® is a cream containing liquid paraffin, white soft paraffin and saturated neutral oil. It also contains cetostearyl alcohol and glyceryl monostearate. Unguentum M® contains many of the excipients in Metvix®. 50 g tubes will be dispensed by the Pharmacy Department, University Hospital of Wales for patients within the placebo group at each visit. It will not be re-packaged. Application to the subject's face will be identical to MAL. IPL Device Parameters: Variable Pulsed Light is an IPL system that allows the operator to change the width, delay and number of the micropulses. The Energist ULTRAÔ VPLÔ System (Energist Ltd., UK) will be used for this study. Device Settings: 530-950 nm cut-off filter; Double passes of: 20-40 J/cm2, 15 pulses, 5 ms duration, 20 ms delay (20 J/cm2, 15 x 5 x 20). Adapalene gel (Differin® Gel 0.1% w/w): Patients will be instructed to apply a thin film of adapalene gel to their faces, after washing it, nightly, avoiding the areas just around the eyes, nostrils and mouth. They will also be told and given written information about the possible side-effects in their patient information leaflets. Added 04/11/09: The number of visits will depend upon which arm of the research project the patient is involved in: the PDT group will make eight visits over 16 weeks and the adapalene group will make five visits over 16 weeks. Treatment compliance: Patients using adapalene will be reminded to apply their medication by methods such as weekly emails. On the assessment days, patients will be asked to bring their adapalene tubes, which will be weighed. The other treatments will be directly administered by the physician. Concomitant treatment: Sunblock lotion (SPF 30; Delph Lotion) will be provided by the department and should be used daily all over the face for the entire duration of the study. An emollient (to be applied twice a day for a total of 5 days) will be given to all patients in the IPL groups post treatment. Patients in the PDT-MAL and the PDT-placebo groups will also be asked to keep daily diary cards for the 44 weeks after the 4-month study period to document the time and severity of relapse and treatments used. The follow-up period is 44 weeks beyond the end of the 16-week treatment period. The two follow-up appointments are at week 38 and 60 Project coordinator details 1. Dr. C A Suthananthan, MSc (Project Coordinator 1) Honorary Clinical Fellow Department of Dermatology 3rd Floor Glamorgan House School of Medicine, Heath Park Cardiff University, CF14 4XN Tel: +44 (0)2920 745875 Fax: +44 (0)2920 744312 Email: SuthananthanCA@cardiff.ac.uk 2. Dr. B. Shaheen, Diploma in Clinical dermatology, MRCP (Project Coordinator 2) Honorary Clinical Fellow Department of Dermatology, 3rd Floor Glamorgan House School of Medicine, Heath Park Cardiff University, CF14 4XN Fax: +44 (0)2920 744312 Email: babar524@hotmail.com |
| Intervention type | Drug |
| Pharmaceutical study type(s) | |
| Phase | Not Applicable |
| Drug / device / biological / vaccine name(s) | Adapalene |
| Primary outcome measure | Current infomation as of 04/11/2009: Lesion counts. The face will be divided into five areas. The types of lesions are classified as macules, comedones, papules, pustules, nodules and cysts. These will be counted in at least one of five possible facial cosmetic units before treatment. Subsequent lesion counts will be repeated in the chosen quadrant. Outcomes will be measured at baseline, weeks 8, 11 and 16 in phase 1 (treatment phase) and weeks 38 and 60 for phase 2 (follow-up phase, PDT arms only). Initial information at time of registration: Lesion counts at baseline, Week 12 and 16, Month 7*, 10*, 13* and 16*. *Follow-up for Months 7 to 16 applies only to the PDT arms. |
| Secondary outcome measures | Current information as of 04/11/2009: 1. Leeds Revised Acne Grading System scores measured at baseline, week 8, 11,16, 38 and 60 2. Seborrhoea measured using SM-815 sebumeter measured at baseline, week 8, 11,16, 38 and 60 3. P. acnes counts and culture measured at baseline, week 8, 11,16 and 60 4. P. acnes fluorescence photography measured at baseline, week 8, 11,16 and 60 5. Acne-specific Quality of Life Assessments (Acne QoL) measured at baseline, week 8, 11,16 and 60 6. Dermatology Life Quality Index (DLQI) measured at baseline, week 8, 11,16 and 60 7. The Family Dermatology Life Quality index (FDLQI) measured at baseline, week 16 and 60 8. Pain scores measured at day 1, week 3, 5, and 7 9. Subjective global assessment of acne improvement measured at baseline, week 8, 11 and 16 Initial information at time of registration: 1. Leeds Revised Acne Grading System scores at baseline, Week 12 and 16, Month 7*, 10*, 13* and 16* 2. Seborrhoea at baseline, Week 12 and 16, Month 7*, 10*, 13* and 16* 3. P. acnes counts at baseline and Week 7 4. P. acnes fluorescence photography. For all arms, this will be carried out at baseline, Weeks 7, 12 and 16, Months 7*, 10*, 13* and 16* 5. Dermatology Life Quality Index (DLQI) and/or Acne Quality of Life scale at baseline, Week 12 and 16 6. Pain scores (only in PDT-MAL and PDT-Placebo arms), assessed by a visual analogue scale (VAS) at Day 1 (Week 1), Week 3, 5 and 7 7. Subjective global assessment of acne improvement at baseline, Weeks 12 and 16 *Follow-up for Months 7 to 16 applies only to the PDT arms. |
| Overall study start date | 01/01/2010 |
| Completion date | 13/08/2012 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Lower age limit | 18 Years |
| Upper age limit | 50 Years |
| Sex | Both |
| Target number of participants | 120 |
| Total final enrolment | 37 |
| Key inclusion criteria | Current information as of 04/11/2009: 1. Aged 18 - 50 years, both males and females 2. Mild to moderate facial (face = area from hair line to jaw line) acne vulgaris with at least 15 inflammatory lesions and/or non-inflammatory lesions, but no more than three nodulocystic lesions. Thus, not exceeding Leeds grade 7. 3. Patients willing to have only their face treated 4. Skin phototypes IIII 5. Patients who are willing and able to provide written informed consent 6. Patients who agree to not use sun-beds or undergo any UV light treatment for 4 weeks prior to entering the study and are willing to minimise the amount of exposure to direct sunlight for the duration of the study 7. Patients who have access to email accounts and are willing to reveal their email addresses to the study team Initial information at time of registration 1. Aged 18 - 50 years, both males and females 2. Mild to moderate facial (face = area from hair line to jaw line) acne vulgaris with at least 15 inflammatory lesions and/or non-inflammatory lesions, but no more than three nodulocystic lesions. Thus, not exceeding Leeds grade 7. 3. Patients willing to have only their face treated 4. Skin phototypes IIII 5. Patients who are willing and able to provide written informed consent 6. Patients who agree to not use sun-beds or undergo any UV light treatment for 4 weeks prior to entering the study and are willing to minimise the amount of exposure to direct sunlight for the duration of the study 7. Patients who own a mobile phone and are willing to reveal their number to and receive text messages from the study team |
| Key exclusion criteria | Current information as of 04/11/2009: 1. Severe acne (>3 nodules and/or cysts present) or presence of scarring 2. Pregnancy and women contemplating pregnancy 3. Lactating females 4. Use of anti-androgen containing contraceptives 5. Mental incompetence 6. History of hypersensitivity to any of the study drugs or their excipients. i.e. adapalene, Metvix™ (e.g. peanut oil, soya), Unguentum M®. 7. Keloids or tendency to heal with keloids 8. Cosmetic treatment: 8.1. In the previous year with collagen, dermabrasion and laser resurfacing. 8.2. Alpha hydroxyl acids within 3 months 8.3. Microdermabrasion within 3 months 9. Photosensitivity disorders e.g. solar urticaria 9.1. Porphyrias or allergy to porphyrins 9.2. Epilepsy 10. Systemic retinoid use in the past 12 months 11. Use of Vitamin A supplements > 2000 IU /day 12. Oral antibiotics and topical retinoids for preceding 4 weeks 13. Systemic medications such as: steroids, immunosuppressant, statins and preparations containing St Johns wort 14. Oral photosensitisers within last 4 weeks (see Patient CRF) 15. Previous treatment with IPL or lasers to the areas of interest within the last 12 months 16. Severe systemic diseases such as: impaired renal or liver function; regional enteritis or ulcerative colitis; a history of antibiotic-associated colitis; severe cardiovascular, neurological disease, or any other disease that may interfere with the evaluation of the study medications 17. Patients with psoriasis, acne rosacea, allergic rashes, bacterial, viral or fungal infections of the facial skin, or other diseases of the facial skin 18. Patients with mild to moderate acne who have not tried over the counter treatment 19. Patients who are unlikely to be available for the duration of the follow-up 20. Persons involved in another clinical trial for the duration of this study 21. Persons who have another member of their household taking part in this study Initial information at time of registration: 1. Severe acne (>2 nodules and/or cysts present) or presence of scarring 2. Pregnancy 3. Use of anti-androgen containing contraceptives 4. Mental incompetence 5. History of hypersensitivity to any of the study drugs or their excipients. i.e. adapalene, Metvix™ (e.g. peanut oil, soya), Unguentum M® 6. Keloids or tendency to heal with keloids 7. Cosmetic treatment: 7.1. In the previous year with collagen, dermabrasion and laser resurfacing 7.2. Alpha hydroxyl acids within the last month 7.3. Microdermabrasion within the last 3 months 8. Photosensitivity disorders e.g. solar urticaria 8.1. Porphyrias or allergy to porphyrins 8.2. Epilepsy 9. Systemic retinoid use in the past 12 months 10. Use of Vitamin A supplements >2000 IU /day 11. Oral antibiotics and topical retinoids for preceding 4 weeks 12. Systemic medications such as: steroids, immunosuppressant, statins and preparations containing St. John's wort 13. Oral photosensitisers within last 4 weeks 14. Previous treatment with intense pulsed light (IPL) or lasers to the areas of interest within the last 12 months 15. Severe systemic diseases such as: impaired renal or liver function; regional enteritis or ulcerative colitis; a history of antibiotic-associated colitis; severe cardiovascular, neurological disease, or any other disease that may interfere with the evaluation of the study medications 16. Patients with psoriasis, acne rosacea, allergic rashes, bacterial, viral or fungal infections of the facial skin, or other diseases of the facial skin 17. Patients who are unlikely to be available for the duration of the follow-up 18. Persons involved in another clinical trial for the duration of this study 19. Persons who have another member of their household taking part in this study |
| Date of first enrolment | 01/01/2010 |
| Date of final enrolment | 01/06/2011 |
Locations
Countries of recruitment
- United Kingdom
- Wales
Study participating centre
Reader in Dermatology
Cardiff
CF14 4XN
United Kingdom
CF14 4XN
United Kingdom
Sponsor information
Cardiff University (UK)
University/education
University/education
Research and Commercial Development
30-36 Newport Road
Cardiff
CF24 0DE
Wales
United Kingdom
| Website | http://www.cardiff.ac.uk |
|---|---|
"ROR" |
https://ror.org/03kk7td41 |
Funders
Funder type
University/education
Cardiff University (UK) - Department of Dermatology
No information available
Results and Publications
| Intention to publish date | |
|---|---|
| Individual participant data (IPD) Intention to share | No |
| IPD sharing plan summary | Not provided at time of registration |
| Publication and dissemination plan | Not provided at time of registration 2014 thesis in http://orca.cf.ac.uk/69644/ |
| IPD sharing plan | Not provided at time of registration |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Basic results | 15/06/2019 | 19/05/2022 | No | No |
Editorial Notes
19/05/2022: EU Clinical Trials Register results added.
21/04/2020: The total final enrolment was added.
23/07/2019: The following changes have been made:
1. The EudraCT number has been added.
2. Thesis added to publication and dissemination plan.
3. The overall trial end date has been changed from 01/06/2011 to 13/08/2012.
4. No publications found, all search options exhausted.
12/04/2017: No publications found in PubMed, verifying study status with principal investigator.
